Parkinson'
Conditions
Interventions
Oral bisphosphonate agent group: taking orally Minodronic Acid Hydrate (50mg) 1 tablet per 4 weeks
Intravenous bisphosphonate agent group: injecting Zoledronic Acid (5mg) 1 ampule per 48 weeks
Sponsors
Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
Department of Neurology, Nishi-Niigata Chuo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.50 years or more of age at the time of the consent 2.Patient with Parkinson's disease diagnosed by a professional neurologist 3.patient with primary osteoporosis as in the following case; ?histroy of any types of fragile fracture ?<80% of young adult mean in dual-energy x-ray absorptiometry 4.untreated patient with bone antiresorptive agent or bone anabolic agent 5.patient obtaining the consent based on the patient's free will 6.patient taking anti-Parkinson's disease agent without dysphasia
Exclusion criteria
Exclusion criteria: 1.patient corresponding to contraindication based on the attached document of the bone antiresorptive agents 2.patient with Hoen-Yahr grade 5 Parkinson's disease 3.patient who is considered not to be suited for this survey
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary evaluation item: change of the mean BMD in the prximal femur 2 years after initial treatment secondary evaluation item: 1.Change of the mean BMD in the proximal femur or lumbar spine 2 years after initial tramentt 2.Change of the bone absorption marker 3.Prevalence of new-onset fragile fracture 4.Correlation between QOL and spinal alignment 5.Longitudinal evaluation of BMD or bone resorption marker Safty assessment: Incidecne of adverse reactions for follow-up period | — |
Countries
Japan
Contacts
Public ContactKei Watanabe
Niigata University Medical and Dental Hospital Orthopaedic Surgery
Outcome results
None listed